Compare · BIIB vs RXRX
BIIB vs RXRX
Side-by-side comparison of Biogen Inc. (BIIB) and Recursion Pharmaceuticals Inc. (RXRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIIB and RXRX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $28.34B, about 16.0x RXRX ($1.77B).
- Over the past year, BIIB is up 50.5% and RXRX is down 35.8% - BIIB leads by 86.3 points.
- BIIB has been more active in the news (14 items in the past 4 weeks vs 11 for RXRX).
- BIIB has more recent analyst coverage (25 ratings vs 10 for RXRX).
- Company
- Biogen Inc.
- Recursion Pharmaceuticals Inc.
- Price
- $191.91-8.23%
- $3.35+1.52%
- Market cap
- $28.34B
- $1.77B
- 1M return
- -4.01%
- +6.35%
- 1Y return
- +50.51%
- -35.76%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 14
- 11
- Recent ratings
- 25
- 10
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is based in Salt Lake City, Utah.
Latest BIIB
- LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
- LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
- Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
- FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease
- FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
- Biogen upgraded by Truist with a new price target
- Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer
- LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026
- LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference® (AAIC®) 2026
- Biogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
Latest RXRX
- Director Borgeson Blake sold $158,500 worth of shares (40,000 units at $3.96) as part of a pre-agreed trading plan, decreasing direct ownership by 0.64% to 6,218,287 units (SEC Form 4)
- Director Dar Zavain was granted 5,109 shares, increasing direct ownership by 2% to 240,764 units (SEC Form 4)
- Director Li Dean Y was granted 3,747 shares, increasing direct ownership by 0.25% to 1,473,329 units (SEC Form 4)
- A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
- Director Borgeson Blake was granted 88,424 shares, increasing direct ownership by 1% to 6,258,287 units (SEC Form 4)
- Director Hershberg Robert was granted 88,424 shares, increasing direct ownership by 120% to 162,156 units (SEC Form 4)
- Director Michor Franziska was granted 88,424 shares, increasing direct ownership by 70% to 215,477 units (SEC Form 4)
- Director Sun Elaine D was granted 88,424 shares, increasing direct ownership by 186% to 135,981 units (SEC Form 4)
- Director Dar Zavain was granted 88,424 shares, increasing direct ownership by 60% to 235,655 units (SEC Form 4)
- Director Bumpus Namandje was granted 88,424 shares and sold $12,602 worth of shares (3,963 units at $3.18) as part of a pre-agreed trading plan, increasing direct ownership by 196% to 127,632 units (SEC Form 4)